Clinical Trial: Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections

Brief Summary:

Acinetobacter species have emerged as agents of serious nosocomial infections in critically ill patients. Only a few effective antibiotics are currently available for the treatment of this pathogen and, therefore, sulbactam is being considered as an alternative treatment option. The aims of this study were to i) reveal the population pharmacokinetics and ii) assess the probability of target attainment (PTA) of sulbactam in septic critically ill patients caused by Acinetobacter spp. infections.

The study was conducted in septic critically ill patients caused by Acinetobacter spp. Each patient received 2 g every 12 h of sulbactam for 10 days, after which PK studies were carried out on day 4 of sulbactam therapy and a Monte Carlo simulation was performed to determine the probability of attaining a specific pharmacodynamic target.

Detailed Summary:
Sponsor: Sutep Jaruratanasirikul

Current Primary Outcome: concentration of sulbactam in plasma [ Time Frame: 12 h profile after 7th of sulbactam ]

Original Primary Outcome: concentration of sulbactam in plasma [ Time Frame: 12 h profile after 7th of sulbsctam ]

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Prince of Songkla University

Dates:
Date Received: February 17, 2016
Date Started: September 2014
Date Completion:
Last Updated: March 21, 2016
Last Verified: March 2016